In recent years, immune checkpoint blocking therapy has shown significant efficacy in the treatment of various types of tumors, but it is helpless against pancreatic cancer, which is known as the "king of cancer
The basic principle of immune checkpoint blocking therapy is based on the activation mechanism of immune cells T cells
For a long time, pancreatic cancer has not responded to immune checkpoint blocking therapy based on programmed death receptors and their ligands
Through a variety of sequencing and screening, the research team found that osteopontin and its ligands are highly expressed in pancreatic tumor tissues, so they selected osteopontin and its ligands as the research object
According to the research of the research group, the inhibitor WDR5-47 can effectively inhibit the expression of osteopontin in pancreatic tumor cells and myeloid-derived suppressor cells, and has great potential to be developed as an immunotherapy single agent for pancreatic cancer
Related paper information: http://dx.
http://dx.
doi.
org/10.
1136/jitc-2021-002624
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
